Nautilus Biotechnology, Inc. (NAUT) stock
NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
$2.36+0.26 (+12.38%)
Close on Nov 17, 2026Market cap $300.60MP/E –Yield –
Nautilus Biotechnology r&d expenses
Research and development expenses are spending on new products and technology.
Nautilus Biotechnology's R&D Expenses for the twelve months ending Sep 30, 2026 was $39.07M, down 11.9% year over year. For fiscal 2025 it was $41.11M, down 18.6% from the year before. The highest annual figure on record is $50.48M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.11M | -18.6% |
| FY2024 | Dec 31, 2024 | $50.48M | +6.8% |
| FY2023 | Dec 31, 2023 | $47.25M | +25.4% |
| FY2022 | Dec 31, 2022 | $37.67M | +28.3% |
| FY2021 | Dec 31, 2021 | $29.35M | +136.1% |
| FY2020 | Dec 31, 2020 | $12.43M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $10.18M | +5.9% |
| Q2 FY2026 | Jun 30, 2026 | $9.61M | -7.5% |
| Q1 FY2026 | Mar 31, 2026 | $9.71M | -15.9% |
| Q4 FY2025 | Dec 31, 2025 | $9.58M | -25.3% |
| Q3 FY2025 | Sep 30, 2025 | $9.61M | -21.8% |
| Q2 FY2025 | Jun 30, 2025 | $10.39M | -16.4% |
| Q1 FY2025 | Mar 31, 2025 | $11.54M | -10.8% |
| Q4 FY2024 | Dec 31, 2024 | $12.82M | +2.9% |
| Q3 FY2024 | Sep 30, 2024 | $12.29M | +2.4% |
| Q2 FY2024 | Jun 30, 2024 | $12.44M | +4.4% |
| Q1 FY2024 | Mar 31, 2024 | $12.93M | +18.9% |
| Q4 FY2023 | Dec 31, 2023 | $12.47M | +30.0% |
| Q3 FY2023 | Sep 30, 2023 | $12.00M | +25.3% |
| Q2 FY2023 | Jun 30, 2023 | $11.91M | +34.5% |
| Q1 FY2023 | Mar 31, 2023 | $10.88M | +12.6% |
| Q4 FY2022 | Dec 31, 2022 | $9.59M | -3.1% |
| Q3 FY2022 | Sep 30, 2022 | $9.57M | +16.1% |
| Q2 FY2022 | Jun 30, 2022 | $8.86M | +38.8% |
| Q1 FY2022 | Mar 31, 2022 | $9.66M | +99.8% |
| Q4 FY2021 | Dec 31, 2021 | $9.89M | +154.1% |
| Q3 FY2021 | Sep 30, 2021 | $8.24M | +148.5% |
| Q2 FY2021 | Jun 30, 2021 | $6.38M | +131.9% |
| Q1 FY2021 | Mar 31, 2021 | $4.84M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.89M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.32M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.75M | – |
See a number that looks wrong?